Overview

BAY73-4506 Probe Substrate Study

Status:
Completed

Trial end date:
2018-07-30

Target enrollment:

Participant gender:

Summary

- To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of CYP 2C8 (rosiglitazone) - To evaluate safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of BAY73-4506 in patients with advanced solid tumors

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Midazolam
Omeprazole
Rosiglitazone
Warfarin